Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis

Rheumatology (United Kingdom)

Volumn 55, Issue 5, 2016, Pages 939-948

  Tsang A Sjoe, Michel W P ^a   Nagelkerke, Sietse Q ^b   Bultink, Irene E M ^a   Geissler, Judy ^b   Tanck, Michael W T ^c   Tacke, Carline E ^b   Ellis, Justine A ^d,e   Zenz, Werner ^f   Bijl, Marc ^g   Berden, Johannes H ^h   De Leeuw, Karina ⁱ   Derksen, Ronald H ^j   Kuijpers, Taco W ^b   Voskuyl, Alexandre E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g MARTINI HOSPITAL   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

Caucasian; Fc gamma receptor; Fc IIc; Fc RIIb; Gene polymorphisms; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

FC RECEPTOR;

ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; LEUKOCYTE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MONOCYTE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEUTROPHIL; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE PROPERTY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84965050705     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev433     Document Type: Article

References (43)

1. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
2. Bouts YMDF, Wolthuis MF, Dirkx E et al. Apoptosis and NET formation in the pathogenesis of SLE. Autoimmunity 2012;45:597-601.
3. Niederer HA, Clatworthy MR, Willcocks LC, Smith KG. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann NY Acad Sci 2010;1183:69-88.
4. Nimmerjahn FJ, Ravetch V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
5. Chen KH, Nishi R, Travers N et al. Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo. Blood 2012;120:4421-31.
6. Tsuboi N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 2008;28:833-46.
7. Niederer HALC, Willcocks TF, Rayner W et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet 2010;19:3282-94.
8. Brown EE, Edberg JC, Kimberly RP. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 2007;40:567-81.
9. Breunis WB, van Mirre EJ, Geissler N et al. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat 2009;30:E640-50.
10. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338-43.
11. Koene HRM, Kleijer J, Algra D et al. Fc gammaRIIIa-158V/ F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
12. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992;89:1274-81.
13. Su KX, Li JC, Edberg J et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J Immunol 2004;172:7192-9.
14. Li LH, Yuan H, Pan HF et al. Role of the Fcgamma receptor IIIA-V/F158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Scand J Rheumatol 2010;39:148-54.
15. Yuan HJD, Ni HF, Pan LH et al. Lack of association of FcgammaRIIIb polymorphisms with systemic lupus erythematosus: a meta-analysis. Rheumatol Int 2011;31:1017-21.
16. Yuan HHF, Pan LH, Li JB et al. Meta analysis on the association between FcgammaRIIa-R/H131 polymorphisms and systemic lupus erythematosus. Mol Biol Rep 2009;36:1053-8.
17. Karassa FB, Trikalinos TA, Ioannidis JP. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002;46:1563-71.
18. Karassa FB, Trikalinos TA, Ioannidis JP. The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int 2003;63:1475-82.
19. Lee YH, Ji JD, Song GG. Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Lupus 2009;18:727-34.
20. Fanciulli MPJ, Norsworthy E, Petretto R et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007;39:721-3.
21. Metes DLK, Ernst WH, Chambers A et al. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. Blood 1998;91:2369-80.
22. van der Heijden JWB, Breunis J, Geissler M et al. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol 2012;188:1318-24.
23. Breunis WB, van Mirre EM, Bruin J et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008;111:1029-38.
24. Ernst L, Metes KD, Herberman RB, Morel PA. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J Mol Med 2002;80:248-57.
25. Su KH, Yang X, Li X et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 2007;178:3272-80.
26. Blank MCRN, Stefanescu E, Masuda F et al. Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005;117:220-7.
27. Nossent JC, Becker-Merok A, Rischmueller M, Lester S. Susceptibility for lupus nephritis by low copy number of the fcgr3b gene is linked to increased levels of pathogenic autoantibodies. Autoimmune Dis 2013;2013:750814
28. Aitman TJR, Dong TJ, Vyse PJ et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006;439:851-5.
29. Manger KR, Repp M, Jansen M et al. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis 2002;61:786-92.
30. Dijstelbloem HMM, Bijl R, Fijnheer RH et al. Fcgamma receptor polymorphisms in systemic lupus erythematosus:association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000;43:2793-800.
31. Pradhan VN, Deshpande A, Nadkarni M et al. Fc gamma R IIIB polymorphisms: their association with clinical manifestations and autoantibodies in SLE patients from western India. Int J Rheum Dis 2010;13:138-43.
32. Grootscholten C, Ligtenberg G, Hagen EC et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42.
33. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
34. Churg J, Bernstein J, Glassrock RJ. Renal Disease:Classification and Atlas of Glomerular Diseases. 2nd edn. New York: Igaky-Shoin.
35. Su K, Wu J, Edberg JC et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. J Immunol 2004;172:7186-91.
36. Veri MCS, Gorlatov H, Li S et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcgammareceptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 2007;121:392-404.
37. Li XJ, Wu T, Ptacek DT et al. Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sci Transl Med 2013;5:216ra175.
38. McKinney CT, Merriman R. Meta-analysis confirms a role for deletion in FCGR3B in autoimmune phenotypes. Hum Mol Genet 2012;21:2370-6.
39. Mueller MP, Barros AS, Witherden AL et al. Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locus. Am J Hum Genet 2013;92:28-40.
40. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33:634-43.
41. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 2011;7:691-9.
42. Leffler JM, Martin B, Gullstrand H et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012;188:3522-31.
43. Hakkim ABG, Furnrohr K, Amann B et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010;107:9813-8.